Singapore has strategically placed itself as the clear center of biotechnology and medical technology (MedTech) innovation in Asia. This has created a lively ecosystem where scientific discovery and business use come together. This city-state, which is often called the “Biopolis of Asia,” has changed from a place where things were made to a global center for life sciences research, advanced therapy development and the design of precise medical devices. The companies that are doing well here do a lot more than make healthcare products. They are also working on new cancer treatments, AI-powered diagnostics, smart implants and scalable platforms for biologics manufacturing. Their work deals with some of the most important health issues facing people today and strengthens Singapore’s position as a key link between Eastern and Western medical markets and a reliable partner for big pharmaceutical companies around the world.
Biotech and MedTech companies in Singapore have to deal with many complicated issues because the country wants to be a “living laboratory” for health innovation. The industry has to deal with many rules that follow strict international standards (like those set by the FDA and EMA) as well as rules that are specific to Asia. Companies here turn academic research from top schools like A*STAR and local universities into useful commercial products. This process requires a lot of scientific knowledge and a lot of money to start a business. Furthermore, Singapore’s focus on fighting diseases that are common in Asia, like certain cancers, dengue and chronic conditions that get worse with age, makes businesses come up with solutions that work for different groups of people. This environment encourages a new kind of business: one that is globally minded, scientifically elite and excels at connecting research, clinical trials and market access across the Asia-Pacific region.
S$4.4 Billion and Counting: The State of Biotech in Singapore
Before we reach the top five players, let me set the stage for you on why Singapore has become such a hot area for biotech and medtech.
The money is real—and it’s growing rapidly.
In 2025 alone, the bio sciences sector in Singapore attracted about S$4.4 billion in investment. That is not venture capital hype. That’s global pharma corporations creating new manufacturing plants. That’s startups closing serious investment rounds. That’s the government doubling down on what works.
To put that number in perspective, a decade ago the sector was hardly on the map. Singapore now is in a head-to-head competition with Boston, Shanghai and Zurich for talent, trials and technology.
The government’s purse is wide open.
The well-known RIE2025 strategy (Research, Innovation and Enterprise) has set aside S$37 billion for R&D in all sectors. Of that, S$1 billion is dedicated to health and biomedical science. That money doesn’t just sit in a bank account. It overflows into awards for entrepreneurs, support for joint research facilities, and cooperation between universities and business.
If you are a biotech founder, you can leverage schemes like the Biomedical Sciences Proof-of-Concept Grant (up to S$250,000) or Startup SG Tech (up to S$500,000 for deep tech). And that’s just the entry-level stuff.
Meet the important players that make it all run.
- HSA (Health Sciences Authority): They’re like Singapore’s FDA. They authorize medications, clinical trials and medical devices. But here’s the problem, they are notoriously approachable. They have pre-submission meetings and its Sanding route gives innovative technologies a fast-track. That’s worth a fortune to a company if you can shave months off the clearance process.
- EDB (Economic Development Board): They are the ones who lure in global biotech corporations to set up shop here. They provide tax benefits, co-funding for capability upgrades and assistance with local regulations. See a Pfizer or Thermo Fisher facility in Singapore? EDB made it happen.
- A*STAR (Agency for Science, Technology and Research): This is Singapore’s hidden weapon. ASTAR has 18 research institutes covering biotech, medtech and advanced manufacturing. They offer co-innovation funds that make shared labs, pricey equipment and world-class scientists available to companies. Interestingly, several of the companies on our list were either spun out of ASTAR or worked with them before raising private money.
What’s in it for you?
Whether you’re an investor searching for the next unicorn, a researcher hoping to commercialise your work or a corporate partner exploring for innovation, Singapore’s ecosystem is designed to help you move faster. The money is available. Regulators are supportive. The research institutions are first class.
These are the companies that have cracked the code on how to play and win in this ecosystem.
Top 5 Biotechnology and MedTech Companies Powering Singapore’s S$4.4 Billion Life Sciences Hub
The following list shows five companies that show how strong, diverse and globally ambitious Singapore’s life sciences sector is. These companies were chosen because they have cutting-edge scientific platforms, are doing well in business, are known around the world and are helping to shape the country’s most important growth areas.
- Esco Lifesciences Group
- ASLAN Pharmaceuticals
- Mirxes
- Biolidics Limited
- EndoMaster Pte Ltd
1. Esco Lifesciences Group
Esco Lifesciences is a key global supplier and innovator, providing the technologies and platforms that make life sciences research and commercial bioproduction possible all over the world. The group is based in Singapore and designs, makes and sells a wide range of equipment for cell and gene therapy workflows, IVF clinics, pharmaceutical production and laboratory research. Esco doesn’t make therapeutic drugs itself, but it does provide the whole ecosystem with reliable, cutting-edge capital equipment, consumables and services. This makes it an essential part of the industry.
Contact Details & Background
- Official Website: https://www.escolifesciences.com/
- Global Headquarters: 21 Changi South Street, 1, Singapore 486777
- Founded: 1978
- Employee Strength: Over 1,200 employees globally, with manufacturing in the USA, Germany, UK, China and Singapore.
- Global Reach: Products sold in over 100 countries.
Awards & Recognition
Always one of the fastest-growing companies in Singapore. The company has won many awards for its excellent exports, innovative ideas and outstanding design, including the highly sought-after Singapore Prestige Brand Award.
Key Attributes
- Enabling Technology Focus: Our main business is selling bioreactors, cell processing systems, incubators, laminar flow cabinets and other important lab and production tools.
- CDMO and Therapeutics Support: Its technologies are very important for contract manufacturers and therapeutic companies that make vaccines and cell-based therapies.
- Vertical integration means that a company controls the whole process, from research and development to making its own equipment. This makes sure that the quality is high and the supply chain is strong.
- Global from Singapore: A wonderful example of a Singapore-based company that is the best in the world at what it does.
Industry standings and impacts
Research institutes, hospitals and biopharma companies all over the world see it as a trustworthy, high-quality partner. Esco’s growth is similar to that of the life sciences sector as a whole and its base in Singapore shows how strong the country is in advanced, precise engineering for biology.
2. ASLAN Pharmaceuticals
ASLAN Pharmaceuticals is a biotechnology company based in Singapore that is currently in the clinical stage. Its main goal is to create immunotherapies that will change the lives of cancer patients. After initial human proof of concept, the company strategically in-licenses differentiated asset candidates with proven mechanisms and moves them through late-stage development for cancers that are common in Asia. The main drug it has is ebsigratinib (ASLAN003), a powerful pill that targets cancers with specific genetic changes. ASLAN is a wonderful example of a capital-efficient R&D model. It builds a targeted oncology pipeline by using global innovation for regional clinical development and partnerships.
Contact Details & Background
- Pitchbook Profile: https://pitchbook.com/profiles/company/59938-30#overview
- Global Headquarters: 83 Clemenceau Avenue, #12-03, UE Square, Singapore 239920
- Founded: 2010
- Listed: Nasdaq Capital Market (ASLN)
- Employee Strength: Approximately 50 employees, with key operations in Singapore and the United States.
Awards & Recognition
ASLAN is a well-known leader in Singapore’s biotech scene and has been used as an example of how to develop biotech companies in the region that focus on cancer research.
Key Attributes
- Singapore HQ and Strategy: This biotech company is based in Singapore and has a clear plan to make treatments for people in Asia.
- Late-Stage Clinical Focus: This company focuses on speeding up mid- to late-stage clinical assets, lowering the risk of early-stage assets and finding the most efficient way to get them to market.
- The main program in the Precision Oncology Pipeline, ebsigratinib, aims to target a specific mutation that can be treated in biliary tract cancer and other solid tumors.
- Strategic Partnership Model: Actively looks for partnerships in development and commercialization to get the most out of its portfolio in important Asian markets.
Industry standings and impacts
ASLAN is considered an agile and strategic player in the oncology space. It shows how a Singapore-based biotech can compete globally by focusing on developing drugs quickly for high-need, targeted cancer indications that are common in its region.
3. Mirxes
Mirxes is a molecular diagnostics company that uses blood tests to find cancers and other diseases early. GASTROClear™ is the main technology behind it. It is the first and only commercially available microRNA blood test for the early detection of gastric cancer. It has been approved by regulators in Singapore and other markets. The company is working at the crossroads of genomics, bioinformatics and clinical diagnostics to make microRNA-based tests for other common cancers. This will allow for preventive, precision healthcare.
Contact Details & Background
- Official Website: https://www.mirxes.com/
- Headquarters: 8A Biomedical Grove, #05-01/02, Neuros, Singapore 138648.
- Founded: 2014
Awards & Recognition
At the ASEAN Innovation Business Platform Awards, GASTROClear™ won the “Best MedTech Solution” award. Mirxes is always mentioned as one of the top innovators in Asian diagnostics.
Key Attributes
- Early Detection Mission: Focused on the crucial time when treatment works best, addressing Asia’s high rate of gastrointestinal cancers.
- Liquid Biopsy Expertise: Uses a simple blood draw (liquid biopsy) to find disease-specific microRNA signatures. This is a less invasive way to do a biopsy than taking tissue samples.
- Commercial Product Launched: This biotech startup is different from many others because it has a CE-marked and locally approved product on the market that makes money and collects real-world data.
- Big Data and AI use machine learning to look at complicated microRNA patterns and find strong diagnostic signatures.
Industry standings and impacts
The industry is recognized as a leader in introducing liquid biopsy for early cancer detection into clinical practice in Asia. Healthcare providers view its tests as effective instruments for screening high-risk populations, potentially preserving lives through timely intervention.
4. Biolidics Limited
Biolidics is a publicly traded medical technology company that has made a new system for finding circulating tumor cells (CTCs) without using labels. Its main platform lets you separate and study rare cancer cells from a patient’s blood sample, which provides important information for diagnosing cancer, predicting its course and keeping an eye on treatment. This technology gives doctors a “liquid biopsy” tool that lets them see how cancer changes and grows in real time, which helps them make personalized treatment decisions without having to do invasive tissue biopsies over and over.
Contact Details & Background
- Official Website: https://www.biolidics.com/
- Headquarters: 11 Lorong 3, Toa Payoh, Block B, #01-13 Jackson Square, Singapore 319579.
- Founded: 2014
- Listed: On the Singapore Exchange (SGX) Mainboard.
Awards & Recognition
Its technology has won several awards for innovation, such as “Most Promising Medtech Startup” at SLINGSHOT and awards from Cleantech Open Asia.
Key Attributes
- Unique Cell Capture Technology: This technology uses a special polymer-coated microfluidic chip to efficiently capture CTCs without using specific biomarkers (label-free).
- Research Use and Clinical Aspiration: Pharmaceutical companies and academic centers use it as a powerful research tool and it could also be used for clinical diagnostics in the future.
- Potential for Companion Diagnostics: Its platform is perfect for making companion diagnostics that can tell which patients will respond to certain targeted therapies.
- Public Company Scrutiny: Its listing on the SGX ensures transparency in its finances and operations.
Industry standings and impacts
Cancer researchers and drug developers value it as a useful tool for learning about cancer biology and how drugs work. As a publicly traded company, it serves as a model for other Singapore MedTech companies seeking to raise capital and expand.
5. EndoMaster Pte Ltd
EndoMaster is a leading company in the field of surgical robotics. They are developing advanced endoscopic robotic systems for surgery that don’t require a lot of cutting. The EndoMaster EASE System, the company’s main product, is designed to perform complex endoscopic submucosal dissection (ESD) and other procedures entirely through natural openings, eliminating the need for external cuts. This technology is meant to make complex cancer removal and gastrointestinal surgeries less invasive, which will lower the amount of pain, infection risk and recovery time for patients.
Contact Details & Background
- Official Website: http://www.endomastermedical.com/
- Headquarters: 60 Paya Lebar Road, #09-14 Paya Lebar Square, Singapore 409051
- Founded: 2009
Awards & Recognition
The company consistently emerges victorious in significant innovation competitions such as the SLINGSHOT MedTech and the Wall Street Journal Asian Innovation Award. He is recognized as a leader in the highly competitive field of surgical robotics.
Key Attributes
- Endoscopic Robotics Niche: This area of robotics is all about making flexible endoscopes into robots that can do procedures deep inside the body. This is a different kind of challenge than making large-scale laparoscopic robots.
- Master-Slave System: Surgeons use a console to control the robotic arms from a distance. This makes the procedure more accurate, stable and comfortable than manual endoscopy.
- Addressing Clinical Need: This product addresses the rising need for minimally invasive treatment of early-stage gastrointestinal cancers, where it is crucial to remove tissue accurately.
- Regulatory Pathway: Actively involved in clinical trials and regulatory processes to get important market approvals.
Industry standings and impacts
It stands as one of the most promising innovators in surgical robotics in Asia. The medical community closely monitors its progress as its technology has the potential to expand access to advanced, incisionless surgery techniques, thereby improving outcomes for numerous patients.
The biotechnology and MedTech industries in Singapore are proof that the country has found a successful formula: a clear vision, smart investments and training the best talent in the world. The five companies like Esco Lifesciences, ASLAN Pharmaceuticals, Mirxes, Biolidics and EndoMaster. They show how diverse the field is, with everything from enabling technologies and advanced therapies to early diagnostics and surgical robotics. Each company is not only part of the global life sciences market, but it also wants to change the way care, manufacturing and scientific discovery are done.
How We Picked the Top 5 (And Why You Can Trust the List)
We didn’t just Google ‘biotech firms Singapore’ and pick the first five names. That would be stupid. Rather, we developed a true, human-driven methodology with precise criteria that matter to anyone concerned about this sector.
Here’s what we looked at:
- Scientific and clinical value:
“We checked that each company is solving a real problem with real science. Not just “we got an app” or “we do consulting”. Real lab work, clinical trials or regulatory approval. If a corporation has peer-reviewed research publications or presentations at prominent conferences, that was a good score. - Recent Funding Success:
He who has the gold makes the rules. We like firms that have raised a lot of money in the recent 18-24 months. For example, in 2025 Mirxes closed a USD$180 million Series D and became a unicorn. And that is the sort of cash that shows investor confidence and ability to scale. We also looked at government funds – companies that have received competitive A*STAR or EDB funding gain extra points. - Regulation Milestones:
It’s easy to say you have a revolutionary product. Getting an HSA approval or FDA clearance or CE mark is much harder. We preferred companies who have actually gone through the regulatory quagmire. Extra points for HSA’s Sanding route or other rapid track certifications. - IMPACT ON MARKET AND PARTNERSHIPS:
“Is this company working with other serious organizations?” we questioned. Credibility signal is strong with partnerships with multinational pharma (Pfizer, Roche, Novartis), big hospitals (SingHealth, NUHS) or research institutions (A*STAR, Duke‑NUS) If a company already has a product in use in clinics or hospitals, so much the better. - Contribution to the ecosystem:
Finally, we looked at whether the company contributes back—mentoring startups, participating in industry groups or working with local colleges. The Singaporean biotech scene is collaborative, and companies who get that tend to stick around.
Notes about data sources
We collected data from publicly available filings, company websites, press sources and government databases (e.g., A*STAR’s annual report and the HSA medical device register). Paid placements were not accepted by us. Every company on this list made the list because of the criteria above.
If you’re asking why a certain company didn’t make the list, it’s normally because they didn’t reach one of these bars— or we missed them. Email us and we’ll take another look.
Quick Comparison: Top 5 Biotech & MedTech Companies in Singapore
| Company | Specialization | Key Milestone / Recent Funding |
|---|---|---|
| Esco Lifesciences Group | Laboratory equipment, bioprocessing tools, and life sciences solutions | Global presence with manufacturing in Singapore, USA, Europe, and China; backed by over US$200M in funding |
| ASLAN Pharmaceuticals | Oncology drugs (targeted therapies for cancer, especially gastric and bile duct cancers) | Listed on Nasdaq; lead drug (varlitinib) completed multiple Phase 2/3 trials; partnership with global pharma |
| Mirxes | Cancer diagnostics using microRNA technology (early detection of stomach, colorectal, lung cancer) | Raised **US$180 million Series D** in 2025; achieved unicorn status (over US$1B valuation) |
| Biolidics Limited | Liquid biopsy and cell capture technology for cancer diagnosis and monitoring | Singapore‑based with patented ClearCell® FX1 system; FDA listed and CE marked; commercial presence in Asia |
| EndoMaster Pte Ltd | Robotic endoscopy for minimally invasive gastrointestinal surgeries | Received S$11.9M in grants and funding; won multiple innovation awards; clinical trials in Singapore and China |
Notes on the data:
- Esco is a quiet giant – not as flashy as a drug startup but they supply labs worldwide and are a cornerstone of Singapore’s biotech infrastructure.
- ASLAN is publicly traded, so their financials and trial data are easy to verify.
- Mirxes made headlines with the unicorn round – that is the most recent major funding event among the five.
- Biolidics focuses on capturing rare cancer cells from blood; their tech is used in research and clinical settings.
- EndoMaster is a medtech device company, different from the biotech drug developers but highly innovative and grant savvy.
Frequently Asked Questions
How much money is really going into Singapore’s biotech and medtech sector today?
Much. The sector drew in about S$4.4 billion in investments in 2025 alone. That’s a lot of money. They are seeing international pharma giants extending their manufacturing footprint, venture capitalists putting their money on local businesses, and government funds fuelling R&D. For comparison, that’s more than double what the sector was bringing in only a few years back. So if you are asking yourself is Singapore a significant player – sure the money says it is.
I hear a lot about “unicorns” in Singapore biotech. Is that actual real?
Certainly. Take Mirxes, for instance. They are a local diagnostics startup that uses micro RNA technology to detect cancer early. In 2025, they closed a $180 million Series D investment round, thus becoming a unicorn (value exceeding $1 billion). That is not a new headline. It suggests investors feel companies can grow globally from Singapore. And they are not alone – numerous other biotech businesses are knocking at the door of unicorn status.
What’s the story with government funding? Are there grants for small start-ups?
Yes, and it’s one of the biggest pluses in Singapore. Under the RIE2025 (Research, Innovation and Enterprise) initiative, the government committed S$37 billion. S$1 billion of that is especially for health and biomedical sciences. That money moves through agencies like A*STAR, EDB and Enterprise Singapore. Schemes like Startup SG Tech and Biomedical Sciences Proof-of-Concept plan can cover up to 85% of your R&D costs. The application procedure is competitive, of course, but many of the enterprises on our list started off with government help.
How long does it take for a medical device to be approved by HSA in Singapore?
That depends on the risk class. For low risk devices (Class A) you could be approved in 30-60 days. For higher risk implants or active devices (Class C and D) budget 6 to 12 months, maybe longer if you need clinical trial results. HSA has been simplifying the process with its Sanding pathway (akin to the FDA’s Breakthrough Device designation) that can shave months off delays. The idea is to get HSA involved early. They offer pre-submission consultations, and employing them can save you from costly delays.
Apart from money, what is the biggest challenge for biotech entrepreneurs in Singapore?
And frankly? Talent. Experienced regulatory affairs managers, clinical trial coordinators, bioinformatics scientists are hard to find. Singapore generates exceptional graduates but strong knowledge in particular fields like cell therapy manufacturing or AI-based diagnostics is rare. Many firms are forced to hire from overseas — which implies work passes and the pain of relocating. The government is trying to help with initiatives like the Global Ready Talent Programme and Tech.Pass but it is still a sore point.” If you are beginning a firm here, expect headhunter expenses.”
Singapore is very much in the news in cell and gene therapy. Why is that so important?
Next up is cell and gene therapy (CGT), such tailored cancer therapies where you alter a patient’s own immune cells. Singapore has quietly emerged as a regional powerhouse for CGT manufacture and clinical testing. CellVec, one of our top 5 companies, is creating lentiviral vectors for use in CAR-T therapy. The government has invested more over S$150 million in the NSCRI (National Stem Cell Research Initiative) and continues to fund CGT research. Why it matters: CGT is notoriously difficult to build and Singapore’s reputation for quality and dependability provides it an edge over other Asian hubs.
How does Singapore stack up against other biotech hotspots like Boston or Shanghai?
Singapore is smaller in terms of raw size. But in terms of ecosystem efficiency it’s punching much above its weight. In the morning you can have a regulatory meeting with HSA, at lunch talk to A*STAR researchers, and in the afternoon meet a venture capitalist – all within a 10km radius. You’d be sitting in traffic in Boston for hours. In Shanghai you’d face language and regulatory barriers. “Singapore’s edge is speed, connectivity. That’s why global corporations like Pfizer, Novartis and Thermo Fisher establish their regional headquarters or big manufacturing operations here.
What does A*STAR do? Do they merely fund research or can they help sell products?
ASTAR (Agency for Science, Technology and Research) is more than a financial agency. Think of them as partners in technology development. They operate 18 research institutes in biotech, medtech and advanced manufacturing. They have shared labs and equipment and even “co-innovation” funds where they will link your company with their scientists. For example, a start-up that is developing an AI-based pathology tool may partner with ASTAR’s Bioinformatics Institute to evaluate their algorithms. Many of the top 5 companies in our list have collaborated with A*STAR to co-develop products before they spun out or raised private finance.
